Login to Your Account

GPC Tumbles On Satraplatin Glitch; Panel Issues Outlined

By Randall Osborne

Monday, July 23, 2007
The pre-panel meeting word from the FDA in online satraplatin briefing documents that walloped GPC Biotech Inc.'s shares - denting licensee Spectrum Pharmaceuticals Inc. and GPC partner Pharmion Corp. as well - could mean a delay of the prostate cancer drug's approval, and for how long is unclear.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription